Navigation Links
Gen-Probe Reports Financial Results for the First Quarter of 2011
Date:4/28/2011

ur ability to achieve results described in any forward-looking statements.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:
Michael Watts
Vice president, investor relations and
corporate communications
858-410-8673Gen-Probe IncorporatedConsolidated Balance Sheets - GAAP(In thousands, except share and per share data)March 31,December 31,20112010(Unaudited)AssetsCurrent assets:Cash and cash equivalents

$  93,563$  59,690Marketable securities

177,908170,648Trade accounts receivable, net of allowance for doubtful accounts
  of $405 and $355 at March 31, 2011 and December 31, 2010,
  respectively

59,63354,739Accounts receivable — other

3,5485,493Inventories

65,18066,416Deferred income tax

13,77413,634Prepaid income tax

262,993Prepaid expenses

13,83711,672Other current assets

5,6985,148Total current assets

433,167390,433Marketable securities, net of current portion

219,808259,317Property, plant and equipment, net

163,538160,863Capitalized software, net

14,01413,981Patents, net

12,32712,450Goodwill

150,639150,308Purchased intangibles, net

118,338120,270License, manufacturing access fees and other assets, net

62,42760,175Total assets

$1,174,258$1,167,797Liabilities and stockholders' equityCurrent liabilities:Accounts payable

$  11,471$  14,614Accrued salaries and employee benefits

19,06626,825Other accrued expenses

16,768
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Gen-Probe to Webcast Three Upcoming Investor Presentations
2. Gen-Probe Announces $150 Million Stock Repurchase Plan
3. Gen-Probe to Webcast Two Upcoming Investor Presentations
4. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
5. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
6. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
7. Neogen Acquires Gen-Probes BioKits Food Safety Business
8. Gen-Probe to Webcast Two Upcoming Investor Presentations
9. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
10. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
11. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... Calif. (PRWEB) , ... September 01, 2015 , ... ... today that Brent Nelson, D.O., has joined its medical management team as an ... serving companies of all sizes and types in the U.S. and abroad. ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
(Date:9/1/2015)... ... ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Be Well videos to prostate cancer awareness. Prostate cancer is the most-common, non-skin cancer ... Mercy Health’s YouTube channel, Mercy Health experts address issues, such as:, ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... its consumer-friendly, informational video this week to coincide with back-to-school and the start ... , According to the CDC, elementary school children are sick an average of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of ... In the last month the FDA has approved two intra-gastric balloons, the ORBERA ... represent the first incisionless, reversible, weight loss procedures available to Americans. , ...
Breaking Medicine News(10 mins):Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... New data pooled from four large, "real world" ... VIII (rFVIII-FS) reduced bleeding and provided data regarding ... mild-to-severe hemophilia A. Additionally, rates of inhibitor formation ... untreated patients. The data were presented at the ...
... , SAN DIEGO, July 13 Victory Pharma, ... (FDA) has accepted for review the New Drug Application (NDA) for ... patients and healthcare providers the advantage of a proven antiemetic agent ... nausea and vomiting. , , "Acceptance ...
... July 13 Uroplasty, Inc. (NYSE Amex: ... and markets innovative proprietary products for the treatment of ... Patent No. 7,536,226 entitled, "Electro-Nerve Stimulator System and Methods." ... stimulation methods for treatment of the overactive bladder ("OAB") ...
... PORT WASHINGTON, N.Y., July 13 Premier Heart, LLC today ... Association has granted a CPT Category III code to Premier ... is the World,s first Internet based, non-invasive, stress, radiation and ... The MCG is intended as an aid for bridging ...
... 13 With summer in full swing, women everywhere are ... to the salon for manicures and pedicures. Starting this month, ... you look great has an added bonus - it ... , Today, Look Good...Feel Better , ...
... ... ... announces updates to its Website, www.prenexa.com . PreNexa® is the first single capsule prenatal ... a day.(1-4) , ,The updated content and offerings on prenexa.com include: , ...
Cached Medicine News:Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 3Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 4Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 5Health News:Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review 2Health News:Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System 2Health News:Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System 3Health News:AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG) 2Health News:Look Good...Feel Better and OPI Celebrate 20 Years of Helping Women Cope With Cancer 2Health News:Upsher-Smith Laboratories, Inc. Updates Prenexa.com with Folic Acid Content, Money-Saving Coupon, and Personalized Address Labels 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: